市场调查报告书

滤泡型淋巴瘤 (FL) 治疗药 - 市场考察,流行病学,市场预测:2030年

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品编码 955853
出版日期 内容资讯 英文 200 Pages
商品交期: 最快1-2个工作天内
价格
滤泡型淋巴瘤 (FL) 治疗药 - 市场考察,流行病学,市场预测:2030年 Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 2020年09月01日内容资讯: 英文 200 Pages
简介

滤泡型淋巴瘤 (FL) 治疗药的市场规模,预计2017年~2030年大幅度成长。在主要7个国家中,美国占最大的市场规模,2017年达到了7亿9900万美元。另一方面,最小在西班牙,2017年是5,600万美元。

本报告提供滤泡型淋巴瘤 (FL) 治疗药调查分析,过去、未来的流行病学,美国、欧洲5个国家 (德国,西班牙,义大利,法国,英国) 、日本的市场趋势为焦点,目前治疗方法,新药,市场规模等相关的系统性资讯。

目录

第1章 主要考察

第2章 滤泡型淋巴瘤 (FL)的摘要整理

第3章 滤泡型淋巴瘤 (FL)的SWOT分析

第4章 滤泡型淋巴瘤 (FL) 市场概要

  • 2017年的滤泡型淋巴瘤 (FL)的市场占有率分布
  • 2030年的滤泡型淋巴瘤 (FL)的市场占有率分布

第5章 疾病的背景和概要

  • 简介
  • 滤泡型淋巴瘤 (FL)的种类
  • 征兆与症状
  • 原因
  • 分期和等级
  • 滤泡型淋巴瘤 (FL)的遗传性形势
  • 病理生理学
  • 诊断

第6章 流行病学和患者族群

  • 主要调查结果
  • 主要7个国家的滤泡型淋巴瘤 (FL)的总发病患者数

第7章 滤泡型淋巴瘤 (FL)的各国流行病学

  • 前提条件与根据:主要7个国家
  • 美国
  • 欧洲5个国家
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
  • 日本

第8章 治疗

第9章 指南

  • 滤泡型淋巴瘤 (FL) 患者的NCCN指南
  • ESMO临床诊疗指南
  • 日本血液学会(JSH)滤泡型淋巴瘤 (FL) 相关指南

第10章 未满足需求

第11章 滤泡型淋巴瘤 (FL) 贡献的组织

第12章 病人旅程

第13章 病例报告

第14章 上市药

  • Tazverik:Epizyme
  • Aliqopa:Bayer Healthcare Pharmaceuticals
  • Copiktra:Verastem Oncology
  • Zydelig:Gilead Sciences

第15章 并用药:上市

第16章 新药

  • Abexinostat:Xynomic Pharmaceuticals, Inc.
  • Umbralisib:TG Therapeutics
  • ME-401:MEI Pharma
  • Odronextamab:Regeneron Pharmaceuticals
  • Parsaclisib:Incyte Corporation
  • Kymriah:Novartis
  • Yescarta:Kite Pharma
  • Nivolumab:Bristol-Myers Squibb
  • Ixazomib:Takeda Oncology

第17章 新的并用药

第18章 其他有力药

  • Atezolizumab:Roche
  • Pembrolizumab:Merck
  • Venetoclax:AbbVie/Genentech
  • Betalutin:Nordic Nanovector ASA
  • Tenalisib:Rhizen Pharmaceuticals

第19章 市场分析滤泡型淋巴瘤 (FL) :主要7个国家

  • 主要调查结果
  • 主要7个国家的滤泡型淋巴瘤 (FL)的市场规模

第20章 市场预测

  • 市场预测主要7个国家
  • 美国的市场规模
  • 欧洲5个国家:市场预测
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
  • 日本:市场预测

第21章 推动市场要素

第22章 市场障碍

第23章 市场进入与偿付

第24章 附录

第25章 DelveInsight的服务内容

第26章 免责声明

第27章 关于DelveInsight

目录
Product Code: DIMI1048

DelveInsight's 'Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Follicular Lymphoma market report provides analysis regarding current treatment practices, and emerging drugs like Tazemetostat (Epizyme, Inc.), Lenalidomide (Celgene Corp.) and CAR-T therapies Kymriah (Novartis) and Yescarta (Kite Pharmaceuticals/Gilead), potential therapies, market share of the individual therapies, historical, current and forecasted Follicular Lymphoma market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Follicular Lymphoma- Disease Understanding and Treatment Algorithm

Follicular Lymphoma Overview

Follicular lymphoma (FL), a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs. The term follicular lymphoma comes from the observation that the cancer cells are the group in clusters (or follicles) within the lymph nodes.

Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no apparent symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable, but more of chronic disease. Besides, patients can live for many years with this form of lymphoma. The exact, underlying cause of FL is not fully understood.

Follicular Lymphoma Treatment

This chapter covers the details of conventional and current medical therapies available in the Follicular Lymphoma market for the treatment of the condition. It also provides the country-wise Follicular Lymphoma treatment guidelines across the United States, Europe, and Japan.

DelveInsight's Follicular Lymphoma market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Follicular Lymphoma treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Follicular Lymphoma Epidemiology

The Follicular Lymphoma epidemiology chapters provide insights about historical and current Follicular Lymphoma patient pool and forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Follicular Lymphoma epidemiology is segmented by Total incident cases of Follicular Lymphoma, Cases of Follicular Lymphoma by Grade, Cases of Follicular Lymphoma by Age and Stage-specific Follicular Lymphoma cases. The report includes a thorough analysis of all segmentations.

In the US, the cases of Follicular Lymphoma were 14,329 in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 in the country.

According to DelveInsight's analysis, the total prevalent population of Follicular Lymphoma in seven major markets was 33,363 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases.

Follicular Lymphoma Drug Chapters

Drug chapter segment of the Follicular Lymphoma report encloses the detailed analysis of Follicular Lymphoma pipeline drug. It also helps understand the Follicular Lymphoma clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Treatment is focused entirely on the management of symptoms and supporting the health and well-being of the affected child or adult. The management of Follicular Lymphoma revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Tazemetostat (Epizyme, Inc.), Lenalidomide (Celgene Corp.) and CAR-T therapies Kymriah (Novartis) and Yescarta (Kite Pharmaceuticals/Gilead) etc. for the treatment of Follicular Lymphoma in the pipeline.

Follicular Lymphoma Market Outlook

The Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.

Follicular Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Follicular Lymphoma market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Follicular Lymphoma market uptake by drugs; patient uptake by therapies; and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Follicular Lymphoma market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Follicular Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Follicular Lymphoma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Follicular Lymphoma collaborations, acquisition and merger, licensing, patent details and other information for Follicular Lymphoma emerging therapies.

Reimbursement Scenario in Follicular Lymphoma

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Follicular Lymphoma domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Follicular Lymphoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, Follicular Lymphoma market scenario is expected to alter across the 7MM due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Follicular Lymphoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Follicular Lymphoma Pipeline Analysis
  • Follicular Lymphoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Follicular Lymphoma Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Follicular Lymphoma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Follicular Lymphoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Follicular Lymphoma market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Follicular Lymphoma total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Follicular Lymphoma market size during the forecast period (2017-2030)?
  • At what CAGR, the Follicular Lymphoma market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Follicular Lymphoma market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Follicular Lymphoma market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Follicular Lymphoma?
  • What is the historical Follicular Lymphoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Follicular Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Follicular Lymphoma?
  • Out of all 7MM countries, which country would have the highest prevalent population of Follicular Lymphoma during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Follicular Lymphoma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Follicular Lymphoma in the USA, Europe, and Japan?
  • What is the Follicular Lymphoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Follicular Lymphoma?
  • How many therapies are developed by each company for Follicular Lymphoma treatment?
  • How many are emerging therapies in mid-stage, and late-stage of development for Follicular Lymphoma treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follicular Lymphoma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Follicular Lymphoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Follicular Lymphoma?
  • What are the global historical and forecasted market of Follicular Lymphoma?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Follicular Lymphoma market
  • To understand the future market competition in the Follicular Lymphoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Follicular Lymphoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Follicular Lymphoma market
  • To understand the future market competition in the Follicular Lymphoma market

Which geography accounted for the largest Follicular Lymphoma market size?

The United States accounted for the largest Follicular Lymphoma market size.

What is forecasted Follicular Lymphoma market size in 2030?

DelveInsight estimates an increase in Follicular Lymphoma Market Size during the study period, 2017-2030

What are the present Follicular Lymphoma market drivers?

Changing standards of care, increasing opportunities and family history aims at driving the market growth.

What are the Follicular Lymphoma market barriers?

Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the market growth.

How many companies are developing drugs for Follicular Lymphoma?

Currently, there are many key pharma players engaged in developing the drug for Follicular Lymphoma in combination and monotherapy both.

Which are the leading companies in Follicular Lymphoma market?

Key Players - Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, etc.

How is epidemiology segmented for Follicular Lymphoma?

Incident Cases of Follicular Lymphoma, Follicular Lymphoma cases by Grade, FL cases by Age and Follicular Lymphoma cases by Stage.

Table of Contents

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. SWOT Analysis for Follicular Lymphoma

4. Follicular Lymphoma Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Follicular Lymphoma in 2017
  • 4.2. Market Share (%) Distribution of Follicular Lymphoma in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Types of Follicular Lymphoma
  • 5.3. Sign and Symptoms
  • 5.4. Causes
  • 5.5. Staging and Grading
  • 5.6. Genetic Landscape of Follicular Lymphoma
  • 5.7. Pathophysiology
  • 5.8. Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Incident Patient Population of Follicular Lymphoma

7. Country Wise-Epidemiology of Follicular Lymphoma

  • 7.1. Assumptions and Rationale - 7MM
  • 7.2. The United States
    • 7.2.1. Total Incident Cases of Follicular Lymphoma in the United States
    • 7.2.2. Grade-specific Cases of Follicular Lymphoma in the United States
    • 7.2.3. Age-specific Cases of Follicular Lymphoma in the United States
    • 7.2.4. Stage-specific Cases of Follicular Lymphoma in the United States
  • 7.3. EU5
    • 7.3.1. Germany
      • 7.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany
      • 7.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany
      • 7.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany
      • 7.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany
    • 7.3.2. France
      • 7.3.2.1. Total Incident Cases of Follicular Lymphoma in France
      • 7.3.2.2. Grade-specific Cases of Follicular Lymphoma in France
      • 7.3.2.3. Age-specific Cases of Follicular Lymphoma in France
      • 7.3.2.4. Stage-specific Cases of Follicular Lymphoma in France
    • 7.3.3. Italy
      • 7.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy
      • 7.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy
      • 7.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy
      • 7.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy
    • 7.3.4. Spain
      • 7.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain
      • 7.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain
      • 7.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain
      • 7.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain
    • 7.3.5. The United Kingdom
      • 7.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom
      • 7.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom
      • 7.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK
      • 7.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK
  • 7.4. Japan
    • 7.4.1. Total Incident Cases of Follicular Lymphoma in Japan
    • 7.4.2. Grade-specific Cases of Follicular Lymphoma in Japan
    • 7.4.3. Age-specific Cases of Follicular Lymphoma in Japan
    • 7.4.4. Stage-specific Cases of Follicular Lymphoma in Japan

8. Treatment

9. Guidelines

  • 9.1. NCCN Guidelines for Patient with Follicular Lymphoma
  • 9.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma
  • 9.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma

10. Unmet Needs

11. Organizations contributing toward Follicular Lymphoma

12. Patient Journey

  • 12.1. A Journey through follicular lymphoma
  • 12.2. Patient Journey: General

13. Case Reports

  • 13.1. Patient Case Study: From Follicular Lymphoma to DLBCL
  • 13.2. Diagnostic Workup for Follicular Lymphoma
  • 13.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma

14. Marketed Therapies

  • 14.1. Tazverik: Epizyme
    • 14.1.1. Product Description
    • 14.1.2. Other Development Activities
    • 14.1.3. Clinical Development
    • 14.1.4. Safety and Efficacy
  • 14.2. Aliqopa: Bayer Healthcare Pharmaceuticals
    • 14.2.1. Product Description
    • 14.2.2. Other Development Activities
    • 14.2.3. Clinical Development
    • 14.2.4. Safety and Efficacy
  • 14.3. Copiktra: Verastem Oncology
    • 14.3.1. Product Description
    • 14.3.2. Other Development Activities
    • 14.3.3. Clinical Development
    • 14.3.4. Safety and Efficacy
  • 14.4. Zydelig: Gilead Sciences
    • 14.4.1. Product Description
    • 14.4.2. Other Development Activities
    • 14.4.3. Clinical Development
    • 14.4.4. Safety and Efficacy

15. Combinational Therapies: Marketed

16. Emerging Therapies

  • 16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.
    • 16.1.1. Product Description
    • 16.1.2. Other Development Activities
    • 16.1.3. Clinical Development
    • 16.1.4. Safety and Efficacy
  • 16.2. Umbralisib: TG Therapeutics
    • 16.2.1. Product Description
    • 16.2.2. Other Development Activities
    • 16.2.3. Clinical Development
    • 16.2.4. Safety and Efficacy
  • 16.3. ME-401: MEI Pharma
    • 16.3.1. Product Description
    • 16.3.2. Other Development Activities
    • 16.3.3. Clinical Development
    • 16.3.4. Safety and Efficacy
  • 16.4. Odronextamab: Regeneron Pharmaceuticals
    • 16.4.1. Product Description
    • 16.4.2. Other Development Activities
    • 16.4.3. Clinical Development
    • 16.4.4. Safety and Efficacy
  • 16.5. Parsaclisib: Incyte Corporation
    • 16.5.1. Product Description
    • 16.5.2. Other Development Activities
    • 16.5.3. Clinical Development
    • 16.5.4. Safety and Efficacy
  • 16.6. Kymriah: Novartis
    • 16.6.1. Product Description
    • 16.6.2. Other Development Activities
    • 16.6.3. Clinical Development
  • 16.7. Yescarta: Kite Pharma
    • 16.7.1. Product Description
    • 16.7.2. Other Development Activities
    • 16.7.3. Clinical Development
    • 16.7.4. Safety and Efficacy
  • 16.8. Nivolumab: Bristol-Myers Squibb
    • 16.8.1. Product Description
    • 16.8.2. Other Development Activities
    • 16.8.3. Clinical Development
    • 16.8.4. Safety and Efficacy
  • 16.9. Ixazomib - Takeda Oncology
    • 16.9.1. Product Description
    • 16.9.2. Other Development Activities
    • 16.9.3. Clinical Development
    • 16.9.4. Safety and Efficacy

17. Emerging Combinational Therapies

  • 17.1. Ibrutinib + Rituximab
  • 17.2. Umbralisib + Ublituximab + Bendamustine
  • 17.3. Zanubrutinib + Obinutuzumab

18. Other Promising Therapies

  • 18.1. Atezolizumab: Roche
    • 18.1.1. Product Description
    • 18.1.2. Other Development Activities
    • 18.1.3. Clinical Development
    • 18.1.4. Safety and Efficacy
  • 18.2. Pembrolizumab: Merck
    • 18.2.1. Product Description
    • 18.2.2. Other Development Activities
    • 18.2.3. Clinical Development
    • 18.2.4. Safety and Efficacy
  • 18.3. Venetoclax - AbbVie/Genentech
    • 18.3.1. Product Description
    • 18.3.2. Other Development Activities
    • 18.3.3. Clinical Development
    • 18.3.4. Safety and Efficacy
  • 18.4. Betalutin: Nordic Nanovector ASA
    • 18.4.1. Product Description
    • 18.4.2. Other Development Activities
    • 18.4.3. Clinical Development
    • 18.4.4. Safety and Efficacy
  • 18.5. Tenalisib: Rhizen Pharmaceuticals
    • 18.5.1. Product Description
    • 18.5.2. Other Development Activities
    • 18.5.3. Clinical Development
    • 18.5.4. Safety and Efficacy

19. Follicular Lymphoma: Seven Major Market Analysis

  • 19.1. Key Findings
  • 19.2. Market Size of Follicular Lymphoma in 7MM

20. Market Outlook

  • 20.1. 7MM Market Outlook
  • 20.2. United States Market Size
  • 20.3. EU-5 Countries: Market Outlook
    • 20.3.1. Germany
    • 20.3.2. France
    • 20.3.3. Italy
    • 20.3.4. Spain
    • 20.3.5. United Kingdom
  • 20.4. Japan: Market Outlook
    • 20.4.1. Total Market Size of Follicular Lymphoma
    • 20.4.2. Market Size of Follicular Lymphoma by Therapies

21. Market Drivers

22. Market Barriers

23. Market Access and Reimbursement

24. Appendix

  • 24.1. Bibliography
  • 24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Tables

  • Table 1: Summary of Follicular Lymphoma Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Prognostic Factors Associated with Follicular Lymphoma
  • Table 3: Staging of Non-Hodgkin Lymphoma
  • Table 4: Biological Factors Associated with Follicular Lymphoma Transformation
  • Table 5: Incident Patient Population of Follicular Lymphoma in 7MM (2017-2030)
  • Table 6: Total Incident Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 7: Grade-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 8: Age-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 9: Stage-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Table 10: Total Incident Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 11: Grade-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 12: Age-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 13: Stage-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Table 14: Total Incident Cases of Follicular Lymphoma in France (2017-2030)
  • Table 15: Grade-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 16: Age-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 17: Stage-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Table 18: Total Incident Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 19: Grade-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 20: Age-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 21: Stage-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Table 22: Total Incident Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 23: Grade-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 24: Age-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 25: Stage-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Table 26: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Table 27: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Table 28: Age-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Table 29: Stage-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Table 30: Total Incident Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 31: Grade-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 32: Age-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 33: Stage-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Table 34: Organizations contributing toward Follicular Lymphoma
  • Table 35: Tazemetostat, Clinical Trial Description, 2020
  • Table 36: Aliqopa, Clinical Trial Description, 2020
  • Table 37: Copiktra, Clinical Trial Description, 2020
  • Table 38: Zydelig, Clinical Trial Description, 2020
  • Table 39: Abexinostat, Clinical Trial Description, 2020
  • Table 40: Umbralisib, Clinical Trial Description, 2020
  • Table 41: ME-401, Clinical Trial Description, 2020
  • Table 42: REGN1979, Clinical Trial Description, 2020
  • Table 43: Parsaclisib, Clinical Trial Description, 2020
  • Table 44: Kymriah, Clinical Trial Description, 2020
  • Table 45: Yescarta, Clinical Trial Description, 2020
  • Table 46: Nivolumab, Clinical Trial Description, 2020
  • Table 47: Ixazomib, Clinical Trial Description, 2020
  • Table 48: Atezolizumab, Clinical Trial Description, 2020
  • Table 49: Pembrolizumab, Clinical Trial Description, 2020
  • Table 50: Venetoclax, Clinical Trial Description, 2020
  • Table 51: Betalutin, Clinical Trial Description, 2020
  • Table 52: Tenalisib, Clinical Trial Description, 2020
  • Table 53: 7 Major Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 54: United States Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 55: The US Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 56: Germany Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 57: Germany Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 58: France Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 59: France Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 60: Italy Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 61: Italy Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 62: Spain Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 63: Spain Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 64: United Kingdom Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 65: The UK Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Table 66: Japan Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Table 67: Japan Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Origin of B-cell Lymphomas
  • Figure 3: Grading of follicular lymphoma
  • Figure 4: Ann Arbor Classification
  • Figure 5: Transformation in Follicular Lymphoma
  • Figure 6: Pathogenesis of Follicular Lymphoma
  • Figure 7: Stepwise Evolution of Follicular Lymphoma
  • Figure 8: Model of Microenvironment in Follicular Lymphoma
  • Figure 9: Transformation in Follicular Lymphoma
  • Figure 10: Incident Patient Population of Follicular Lymphoma in 7MM (2017-2030)
  • Figure 11: Total Incident Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 12: Grade-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 13: Age-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 14: Stage-specific Cases of Follicular Lymphoma in the United States (2017-2030)
  • Figure 15: Total Incident Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 16: Grade-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 17: Age-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 18: Stage-specific Cases of Follicular Lymphoma in Germany (2017-2030)
  • Figure 19: Total Incident Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 20: Grade-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 21: Age-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 22: Stage-specific Cases of Follicular Lymphoma in France (2017-2030)
  • Figure 23: Total Incident Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 24: Grade-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 25: Age-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 26: Stage-specific Cases of Follicular Lymphoma in Italy (2017-2030)
  • Figure 27: Total Incident Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 28: Grade-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 29: Age-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 30: Stage-specific Cases of Follicular Lymphoma in Spain (2017-2030)
  • Figure 31: Total Incident Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Figure 32: Grade-specific Cases of Follicular Lymphoma in the United Kingdom (2017-2030)
  • Figure 33: Age-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Figure 34: Stage-specific Cases of Follicular Lymphoma in the UK (2017-2030)
  • Figure 35: Total Incident Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 36: Grade-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 37: Age-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 38: Stage-specific Cases of Follicular Lymphoma in Japan (2017-2030)
  • Figure 39: High tumor burden criteria in FL [Groupe d'Etude des Lymphomes Folliculaires (GELF)]
  • Figure 40: Follicular Lymphoma-specific International Prognostic Index' (FLIPI) risk factors
  • Figure 41: Treatment Algorithm
  • Figure 42: Standard first-line therapy of Follicular Lymphoma
  • Figure 43: Overview of evidence-based staging, prognostic tools and strategies and treatment of FL
  • Figure 44: Follow-up Care for FL
  • Figure 45: Guidelines for Follicular Lymphoma (Grade 1-2)
  • Figure 46: Guidelines for Follicular Lymphoma
  • Figure 47: Guidelines for Follicular Lymphoma (treatment/follow-up)
  • Figure 48: Guidelines for Follicular Lymphoma (transformation)
  • Figure 49: Guidelines for Follicular Lymphoma (suggested treatment regimens)
  • Figure 50: Guidelines for Follicular Lymphoma (Criteria's)
  • Figure 51: Treatment Algorithm
  • Figure 52: Treatment Algorithm for Low-tumor burden
  • Figure 53: Treatment Algorithm for High-tumor burden
  • Figure 54: Treatment Algorithm for High-tumor burden
  • Figure 55: Unmet Needs of Follicular Lymphoma
  • Figure 56: Biomarkers in Follicular Lymphoma
  • Figure 57: Biomarkers in Follicular Lymphoma
  • Figure 58: Open Questions in Follicular Lymphoma
  • Figure 59: 7 Major Market Size of Follicular Lymphoma in USD Million (2017-2030)
  • Figure 60: Market Size of Follicular Lymphoma in the United States, USD Million (2017-2030)
  • Figure 61: The US Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 62: Market Size of Follicular Lymphoma in Germany, USD Million (2017-2030)
  • Figure 63: Germany Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 64: Market Size of Follicular Lymphoma in France USD Million (2017-2030)
  • Figure 65: France Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 66: Market Size of Follicular Lymphoma in Italy, USD Million (2017-2030)
  • Figure 67: Italy Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 68: Market Size of Follicular Lymphoma in Spain, USD Million (2017-2030)
  • Figure 69: Spain Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 70: Market Size of Follicular Lymphoma in the United Kingdom, USD Million (2017-2030)
  • Figure 71: The UK Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 72: Market Size of Follicular Lymphoma in Japan, USD Million (2017-2030)
  • Figure 73: Japan Market Size of Follicular Lymphoma by Therapies in USD Million (2017-2030)
  • Figure 74: Market Drivers
  • Figure 75: Market Barriers
  • Figure 76: Healthcare Costs by Regimen in the United States
  • Figure 77: Cost-effectiveness of Treatments